{"id":5697,"date":"2022-08-25T04:30:32","date_gmt":"2022-08-25T04:30:32","guid":{"rendered":"\/\/smallcapscn.x5view.co\/?p=5697"},"modified":"2023-08-29T17:55:20","modified_gmt":"2023-08-29T17:55:20","slug":"prescient-therapeutics-progress-innovative-pipeline-cancer-treatments-capital-raise","status":"publish","type":"post","link":"https:\/\/smallcapscn.x5view.co\/?p=5697","title":{"rendered":"Prescient Therapeutics \u901a\u8fc7\u878d\u8d44\u63a8\u8fdb\u764c\u75c7\u6cbb\u7597\u7684\u521b\u65b0\u7ba1\u9053"},"content":{"rendered":"

Prescient Therapeutics (ASX: PTX) \u542f\u52a8\u4e86\u4e00\u9879\u76ee\u6807\u4e3a 800 \u4e07\u6fb3\u5143\u7684\u878d\u8d44\uff0c\u4ee5\u4fdd\u6301\u5176\u5728\u5f00\u53d1\u521b\u65b0\u764c\u75c7\u548c\u7ec6\u80de\u7597\u6cd5\u7ba1\u9053\u65b9\u9762\u7684\u52bf\u5934\uff0c\u5e76\u8f6c\u5411\u9996\u6b21\u4eba\u4f53\u4e34\u5e8a\u7814\u7a76\u3002<\/p>\n

Prescient \u62e5\u6709\u5e7f\u6cdb\u7684\u4e2a\u6027\u5316\u764c\u75c7\u6cbb\u7597\u7ba1\u9053\uff0c\u5305\u62ec\u4e24\u4e2a\u7ec6\u80de\u6cbb\u7597\u5e73\u53f0\uff08OmniCAR \u548c CellPryme-M\uff09\u548c\u8de8\u8d8a\u4e00\u7cfb\u5217\u4e0d\u540c\u764c\u75c7\u7684\u9776\u5411\u6cbb\u7597\u3002<\/p>\n

Prescient \u7684\u65d7\u8230 OmniCAR \u7ec6\u80de\u6cbb\u7597\u5e73\u53f0\u6709\u53ef\u80fd\u901a\u8fc7\u63d0\u9ad8\u4efb\u4f55 CAR-T \u7597\u6cd5\u7684\u53ef\u63a7\u6027\u3001\u9488\u5bf9\u6027\u3001\u7075\u6d3b\u6027\u3001\u53ef\u6301\u7eed\u6027\u548c\u6210\u672c\u6548\u76ca\u6765\u63d0\u5347\u5b83\u3002<\/p>\n

OmniCAR \u7531 UPenn \u548cOxford\u5f00\u53d1\u5e76\u72ec\u5bb6\u6388\u6743\u7ed9 Prescient\uff0c\u53ef\u7528\u4e8e\u4efb\u4f55\u7ec6\u80de\u3001\u4efb\u4f55\u764c\u75c7\uff0c\u5e76\u4e0e\u4efb\u4f55\u5408\u4f5c\u4f19\u4f34\u5408\u4f5c\u3002<\/p>\n

6 \u6708\uff0cPrescient \u63a8\u51fa\u4e86\u4e0e\u4e16\u754c\u9886\u5148\u7684 Peter MacCallum \u764c\u75c7\u4e2d\u5fc3\u5408\u4f5c\u5f00\u53d1\u7684 CellPryme-M \u5e73\u53f0\u3002\u7b2c\u4e8c\u4e2a\u5e73\u53f0\u65e8\u5728\u63d0\u9ad8 CAR-T \u7597\u6cd5\u7684\u529f\u6548\u548c\u5bff\u547d\uff0c\u53ef\u4e0e\u6216\u4e0d\u4e0e OmniCAR \u4e00\u8d77\u4f7f\u7528\uff0c\u4ee5\u8865\u5145\u5176\u4f18\u52bf\u3002<\/p>\n

\u516c\u53f8\u8fd8\u4e13\u6ce8\u4e8e\u9776\u5411\u836f\u7269 PTX-100 \u548c PTX-200 \u7684\u4e34\u5e8a\u5f00\u53d1\uff0c\u7528\u4e8e\u6cbb\u7597 T \u7ec6\u80de\u6dcb\u5df4\u7624\u548c\u96be\u6cbb\u6027\u6025\u6027\u9ad3\u7ec6\u80de\u767d\u8840\u75c5 (AML) \u7b49\u7f55\u89c1\u4e14\u96be\u4ee5\u6cbb\u7597\u7684\u764c\u75c7\u60a3\u8005\u3002<\/p>\n

\u9664\u6b64\u4e4b\u5916\uff0cPrescient \u8fd8\u4e0e Peter Mac \u4e00\u8d77\u5f00\u53d1\u4e86\u4e09\u79cd\u5185\u90e8 CAR-T \u7597\u6cd5\uff0c\u7528\u4e8e\u6cbb\u7597\u4e25\u91cd\u7684\u764c\u75c7\u80f6\u8d28\u6bcd\u7ec6\u80de\u7624\uff08 GBM \uff09\u548c AML \u5b9e\u4f53\u7624\u3002<\/p>\n

\u8fd9\u4e9b\u57fa\u4e8e OmniCAR \u6280\u672f\uff0c\u672a\u6765\u8fd8\u5c06\u4f7f\u7528 CellPryme\uff0c\u56e0\u6b64\u4e5f\u53ef\u4f5c\u4e3a\u6f5c\u5728\u5e73\u53f0\u5408\u4f5c\u4f19\u4f34\u7684\u6982\u5ff5\u8bc1\u660e\u3002<\/p>\n

\u7b79\u96c6\u8d44\u91d1\u4ee5\u8d44\u52a9\u7ba1\u9053\u8fdb\u5c55<\/h2>\n

\u6839\u636e\u65b0\u80a1\u4efd\u8d2d\u4e70\u8ba1\u5212\u7684\u6761\u6b3e\uff0c\u7b26\u5408\u6761\u4ef6\u7684\u6295\u8d44\u8005\u5c06\u80fd\u591f\u4ee5\u6bcf\u80a1 0.175 \u6fb3\u5143\u7684\u4ef7\u683c\u7533\u8bf7\u4ef7\u503c\u9ad8\u8fbe 30,000 \u6fb3\u5143\u7684\u7f34\u8db3\u666e\u901a\u80a1\u3002<\/p>\n

\u76f8\u5f53\u4e8e\u8fc7\u53bb 5 \u5929\u6210\u4ea4\u91cf\u52a0\u6743\u5e73\u5747\u4ef7\u7684 14.6% \u6298\u8ba9\u548c 8 \u6708 23 \u65e5\u6536\u76d8\u4ef7\u7684 16.7% \u6298\u8ba9\u3002<\/p>\n

\u7b79\u96c6\u7684\u8d44\u91d1\u5c06\u7528\u4e8e\u63a8\u8fdb Prescient \u521b\u65b0\u764c\u75c7\u7597\u6cd5\u7684\u6df1\u5ea6\u7ba1\u9053\u7684\u6301\u7eed\u5f00\u53d1\uff0c\u5373\u5176\u9776\u5411\u7597\u6cd5 PTX-100\u548c PTX-200\u7684\u6301\u7eed\u4e34\u5e8a\u5f00\u53d1\uff0c\u4ee5\u53ca\u5c06\u5176\u521b\u65b0\u7ec6\u80de\u7597\u6cd5\u63a8\u8fdb\u5e76\u8fdb\u5165\u9996\u6b21\u975e\u4eba\u7c7b\u4e34\u5e8a\u7814\u7a76\u3002<\/p>\n

\u8d44\u91d1\u8fd8\u5c06\u6db5\u76d6\u4e00\u822c\u8425\u8fd0\u8d44\u91d1\u548c\u91c7\u8d2d\u8ba1\u5212\u6210\u672c\u3002<\/p>\n

\u6210\u957f\u8f68\u8ff9<\/h2>\n

\u8463\u4e8b\u603b\u7ecf\u7406 Steven Yatomi-Clarke \u8868\u793a\uff0c\u6b64\u6b21\u878d\u8d44\u5c06\u5bfb\u6c42\u5efa\u7acb\u5728 Prescient \u6700\u8fd1\u7684\u589e\u957f\u8f68\u8ff9\u4e4b\u4e0a\u3002<\/p>\n

\u201c\u8fc7\u53bb\u51e0\u5e74\u5bf9\u6211\u4eec\u6765\u8bf4\u662f\u4e00\u4e2a\u4ee4\u4eba\u96be\u4ee5\u7f6e\u4fe1\u7684\u8fdb\u6b65\u65f6\u671f\uff0c\u6211\u4eec\u6b63\u5728\u5bfb\u6c42\u4fdd\u6301\u8fd9\u79cd\u52bf\u5934\uff0c\u5e76\u5c06\u81ea\u5df1\u5b9a\u4f4d\u5728\u80bf\u7624\u5b66\u521b\u65b0\u7684\u524d\u6cbf\uff0c\u201d\u4ed6\u8bf4\u3002<\/p>\n

\u201c\u6211\u4eec\u5f88\u9ad8\u5174\u80fd\u591f\u901a\u8fc7\u4ee5\u9002\u5ea6\u6298\u6263\u4ef7\u8d2d\u4e70\u65b0\u80a1\uff0c\u4e3a\u6211\u4eec\u7684\u80a1\u4e1c\u63d0\u4f9b\u53c2\u4e0e\u6b64\u6b21\uff08\u878d\u8d44\uff09\u7684\u673a\u4f1a\uff0c\u800c\u4e0d\u4f1a\u4ea7\u751f\u7ecf\u7eaa\u6216\u4ea4\u6613\u6210\u672c\u3002\u201d<\/p>\n

\u764c\u75c7\u8bd5\u9a8c<\/h2>\n

4 \u6708\uff0cPrescient \u5f00\u59cb\u62db\u52df\u60a3\u8005\u8fdb\u884c\u6269\u5927\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u8bc4\u4f30 PTX-100 \u6cbb\u7597\u4fb5\u88ad\u6027\u7f55\u89c1\u8840\u764c\uff08\u79f0\u4e3a T \u7ec6\u80de\u6dcb\u5df4\u7624\uff09\u7684\u6548\u679c<\/a>\u3002<\/p>\n

\u8fd9\u9879\u5f00\u653e\u6807\u7b7e\u3001\u975e\u968f\u673a\u8bd5\u9a8c\u5c06\u62db\u52df\u591a\u8fbe 12 \u540d\u590d\u53d1\u548c\u96be\u6cbb\u6027\u6dcb\u5df4\u7624\u60a3\u8005\uff0c\u7531\u58a8\u5c14\u672cEpworth Hospital\u7684\u4e16\u754c\u8457\u540d\u8840\u6db2\u5b66\u5bb6 H Miles Prince \u6559\u6388\u9886\u5bfc\u3002<\/p>\n

\u4e00\u4e2a\u6708\u540e\uff0c\u8be5\u516c\u53f8\u5ba3\u5e03\u5728\u89c2\u5bdf\u5230\u7b2c\u56db\u6b21\u5b8c\u5168\u7f13\u89e3\u540e\uff0c\u5c06\u6269\u5927 PTX-200\u548c\u5316\u7597\u836f\u7269\u963f\u7cd6\u80de\u82f7\u6cbb\u7597\u590d\u53d1\u548c\u96be\u6cbb\u6027 AML \u60a3\u8005\u7684 1b \u671f\u4e34\u5e8a\u7814\u7a76\u961f\u5217\u3002<\/p>\n

Prescient \u8868\u793a\u5c06\u62db\u52df\u4e09\u540d\u65b0\u60a3\u8005\uff0c\u4ee5\u8fdb\u4e00\u6b65\u63a2\u7d22\u8be5\u836f\u7269\u5728\u8be5\u5242\u91cf\u6c34\u5e73\u4e0b\u7684\u5b89\u5168\u6027\u548c\u6709\u6548\u6027\u3002<\/p>\n

\u6b64\u5916\uff0c\u5df2\u786e\u5b9a\u5148\u524d\u63a5\u53d7\u8f83\u4f4e\u5242\u91cf PTX-200 \u6cbb\u7597\u7684\u4e00\u540d\u60a3\u8005\u5728\u51cf\u8f7b\u764c\u75c7\u8d1f\u62c5\uff08\u6216\u4f53\u5185\u764c\u75c7\u6570\u91cf\uff09\u65b9\u9762\u6709\u90e8\u5206\u53cd\u5e94\u3002<\/p>\n","protected":false},"excerpt":{"rendered":"

Prescient Therapeutics (ASX: PTX) \u542f\u52a8\u4e86\u4e00\u9879\u76ee\u6807\u4e3a 800 \u4e07\u6fb3\u5143\u7684\u878d\u8d44\uff0c\u4ee5\u4fdd\u6301\u5176\u5728\u5f00\u53d1\u521b\u65b0\u764c\u75c7\u548c\u7ec6\u80de\u7597\u6cd5\u7ba1\u9053\u65b9\u9762\u7684\u52bf\u5934\uff0c\u5e76\u8f6c\u5411\u9996\u6b21\u4eba\u4f53\u4e34\u5e8a\u7814\u7a76\u3002 Prescient \u62e5\u6709\u5e7f\u6cdb\u7684\u4e2a\u6027\u5316\u764c\u75c7\u6cbb\u7597\u7ba1\u9053\uff0c\u5305\u62ec\u4e24\u4e2a\u7ec6\u80de\u6cbb\u7597\u5e73\u53f0\uff08OmniCAR \u548c CellPryme-M\uff09\u548c\u8de8\u8d8a\u4e00\u7cfb\u5217\u4e0d\u540c\u764c\u75c7\u7684\u9776\u5411\u6cbb\u7597\u3002 Prescient \u7684\u65d7\u8230 OmniCAR \u7ec6\u80de\u6cbb\u7597\u5e73\u53f0\u6709\u53ef\u80fd\u901a\u8fc7\u63d0\u9ad8\u4efb\u4f55 CAR-T \u7597\u6cd5\u7684\u53ef\u63a7\u6027\u3001\u9488\u5bf9\u6027\u3001\u7075\u6d3b\u6027\u3001\u53ef\u6301\u7eed\u6027\u548c\u6210\u672c\u6548\u76ca\u6765\u63d0\u5347\u5b83\u3002 OmniCAR \u7531 UPenn \u548cOxford\u5f00\u53d1\u5e76\u72ec\u5bb6\u6388\u6743\u7ed9 Prescient\uff0c\u53ef\u7528\u4e8e\u4efb\u4f55\u7ec6\u80de\u3001\u4efb\u4f55\u764c\u75c7\uff0c\u5e76\u4e0e\u4efb\u4f55\u5408\u4f5c\u4f19\u4f34\u5408\u4f5c\u3002 6 \u6708\uff0cPrescient \u63a8\u51fa\u4e86\u4e0e\u4e16\u754c\u9886\u5148\u7684 Peter MacCallum \u764c\u75c7\u4e2d\u5fc3\u5408\u4f5c\u5f00\u53d1\u7684 CellPryme-M \u5e73\u53f0\u3002\u7b2c\u4e8c\u4e2a\u5e73\u53f0\u65e8\u5728\u63d0\u9ad8 CAR-T \u7597\u6cd5\u7684\u529f\u6548\u548c\u5bff\u547d\uff0c\u53ef\u4e0e\u6216\u4e0d\u4e0e OmniCAR \u4e00\u8d77\u4f7f\u7528\uff0c\u4ee5\u8865\u5145\u5176\u4f18\u52bf\u3002 \u516c\u53f8\u8fd8\u4e13\u6ce8\u4e8e\u9776\u5411\u836f\u7269 PTX-100 \u548c PTX-200 \u7684\u4e34\u5e8a\u5f00\u53d1\uff0c\u7528\u4e8e\u6cbb\u7597 T \u7ec6\u80de\u6dcb\u5df4\u7624\u548c\u96be\u6cbb\u6027\u6025\u6027\u9ad3\u7ec6\u80de\u767d\u8840\u75c5 (AML) \u7b49\u7f55\u89c1\u4e14\u96be\u4ee5\u6cbb\u7597\u7684\u764c\u75c7\u60a3\u8005\u3002 \u9664\u6b64\u4e4b\u5916\uff0cPrescient \u8fd8\u4e0e Peter Mac \u4e00\u8d77\u5f00\u53d1\u4e86\u4e09\u79cd\u5185\u90e8 CAR-T \u7597\u6cd5\uff0c\u7528\u4e8e\u6cbb\u7597\u4e25\u91cd\u7684\u764c\u75c7\u80f6\u8d28\u6bcd\u7ec6\u80de\u7624\uff08 GBM \uff09\u548c AML \u5b9e\u4f53\u7624\u3002 \u8fd9\u4e9b\u57fa\u4e8e… Continue reading Prescient Therapeutics \u901a\u8fc7\u878d\u8d44\u63a8\u8fdb\u764c\u75c7\u6cbb\u7597\u7684\u521b\u65b0\u7ba1\u9053<\/span><\/a><\/p>\n","protected":false},"author":4,"featured_media":19343,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[3],"tags":[171],"yoast_head":"\nPrescient Therapeutics \u901a\u8fc7\u878d\u8d44\u63a8\u8fdb\u764c\u75c7\u6cbb\u7597\u7684\u521b\u65b0\u7ba1\u9053<\/title>\n<meta name=\"description\" content=\"Prescient Therapeutics (ASX: PTX) \u542f\u52a8\u4e86\u4e00\u9879\u76ee\u6807\u4e3a 800 \u4e07\u6fb3\u5143\u7684\u878d\u8d44\uff0c\u4ee5\u4fdd\u6301\u5176\u5728\u5f00\u53d1\u521b\u65b0\u764c\u75c7\u548c\u7ec6\u80de\u7597\u6cd5\u7ba1\u9053\u65b9\u9762\u7684\u52bf\u5934\uff0c\u5e76\u8f6c\u5411\u9996\u6b21\u4eba\u4f53\u4e34\u5e8a\u7814\u7a76\u3002\" \/>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Prescient Therapeutics \u901a\u8fc7\u878d\u8d44\u63a8\u8fdb\u764c\u75c7\u6cbb\u7597\u7684\u521b\u65b0\u7ba1\u9053\" \/>\n<meta property=\"og:description\" content=\"Prescient Therapeutics (ASX: PTX) \u542f\u52a8\u4e86\u4e00\u9879\u76ee\u6807\u4e3a 800 \u4e07\u6fb3\u5143\u7684\u878d\u8d44\uff0c\u4ee5\u4fdd\u6301\u5176\u5728\u5f00\u53d1\u521b\u65b0\u764c\u75c7\u548c\u7ec6\u80de\u7597\u6cd5\u7ba1\u9053\u65b9\u9762\u7684\u52bf\u5934\uff0c\u5e76\u8f6c\u5411\u9996\u6b21\u4eba\u4f53\u4e34\u5e8a\u7814\u7a76\u3002\" \/>\n<meta property=\"og:url\" content=\"https:\/\/smallcapscn.x5view.co\/prescient-therapeutics-progress-innovative-pipeline-cancer-treatments-capital-raise\/\" \/>\n<meta property=\"og:site_name\" content=\"smallcapsCN\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-25T04:30:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-08-29T17:55:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/smallcapscn.x5view.co\/wp-content\/uploads\/2023\/08\/Prescient-Therapeutics-ASX-PTX-oncology-PTX-100-PTX-200-cancer-drugs.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"640\" \/>\n\t<meta property=\"og:image:height\" content=\"400\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Imelda Cotton\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Imelda Cotton\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/prescient-therapeutics-progress-innovative-pipeline-cancer-treatments-capital-raise\/\",\"url\":\"https:\/\/smallcapscn.x5view.co\/prescient-therapeutics-progress-innovative-pipeline-cancer-treatments-capital-raise\/\",\"name\":\"Prescient Therapeutics \u901a\u8fc7\u878d\u8d44\u63a8\u8fdb\u764c\u75c7\u6cbb\u7597\u7684\u521b\u65b0\u7ba1\u9053\",\"isPartOf\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/#website\"},\"datePublished\":\"2022-08-25T04:30:32+00:00\",\"dateModified\":\"2023-08-29T17:55:20+00:00\",\"author\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/cb7c1f9e2fb318e8ea5882e380e0d90e\"},\"description\":\"Prescient Therapeutics (ASX: PTX) \u542f\u52a8\u4e86\u4e00\u9879\u76ee\u6807\u4e3a 800 \u4e07\u6fb3\u5143\u7684\u878d\u8d44\uff0c\u4ee5\u4fdd\u6301\u5176\u5728\u5f00\u53d1\u521b\u65b0\u764c\u75c7\u548c\u7ec6\u80de\u7597\u6cd5\u7ba1\u9053\u65b9\u9762\u7684\u52bf\u5934\uff0c\u5e76\u8f6c\u5411\u9996\u6b21\u4eba\u4f53\u4e34\u5e8a\u7814\u7a76\u3002\",\"breadcrumb\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/prescient-therapeutics-progress-innovative-pipeline-cancer-treatments-capital-raise\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/smallcapscn.x5view.co\/prescient-therapeutics-progress-innovative-pipeline-cancer-treatments-capital-raise\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/prescient-therapeutics-progress-innovative-pipeline-cancer-treatments-capital-raise\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/smallcapscn.x5view.co\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Prescient Therapeutics \u901a\u8fc7\u878d\u8d44\u63a8\u8fdb\u764c\u75c7\u6cbb\u7597\u7684\u521b\u65b0\u7ba1\u9053\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#website\",\"url\":\"https:\/\/smallcapscn.x5view.co\/\",\"name\":\"smallcapsCN\",\"description\":\"Just another WordPress site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/smallcapscn.x5view.co\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/cb7c1f9e2fb318e8ea5882e380e0d90e\",\"name\":\"Imelda Cotton\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/171e68cb4a3261dde883daa03441bfa3?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/171e68cb4a3261dde883daa03441bfa3?s=96&d=mm&r=g\",\"caption\":\"Imelda Cotton\"},\"description\":\"Imelda Cotton has over 20 years experience as a journalist and communications professional. She has spent the bulk of her career in the resources sector, having also worked directly with oil and gas majors and as a journalist covering a vast array of ASX listed companies within the resources, energy, science and health sectors.\",\"url\":\"https:\/\/smallcapscn.x5view.co\/?author=4\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Prescient Therapeutics \u901a\u8fc7\u878d\u8d44\u63a8\u8fdb\u764c\u75c7\u6cbb\u7597\u7684\u521b\u65b0\u7ba1\u9053","description":"Prescient Therapeutics (ASX: PTX) \u542f\u52a8\u4e86\u4e00\u9879\u76ee\u6807\u4e3a 800 \u4e07\u6fb3\u5143\u7684\u878d\u8d44\uff0c\u4ee5\u4fdd\u6301\u5176\u5728\u5f00\u53d1\u521b\u65b0\u764c\u75c7\u548c\u7ec6\u80de\u7597\u6cd5\u7ba1\u9053\u65b9\u9762\u7684\u52bf\u5934\uff0c\u5e76\u8f6c\u5411\u9996\u6b21\u4eba\u4f53\u4e34\u5e8a\u7814\u7a76\u3002","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Prescient Therapeutics \u901a\u8fc7\u878d\u8d44\u63a8\u8fdb\u764c\u75c7\u6cbb\u7597\u7684\u521b\u65b0\u7ba1\u9053","og_description":"Prescient Therapeutics (ASX: PTX) \u542f\u52a8\u4e86\u4e00\u9879\u76ee\u6807\u4e3a 800 \u4e07\u6fb3\u5143\u7684\u878d\u8d44\uff0c\u4ee5\u4fdd\u6301\u5176\u5728\u5f00\u53d1\u521b\u65b0\u764c\u75c7\u548c\u7ec6\u80de\u7597\u6cd5\u7ba1\u9053\u65b9\u9762\u7684\u52bf\u5934\uff0c\u5e76\u8f6c\u5411\u9996\u6b21\u4eba\u4f53\u4e34\u5e8a\u7814\u7a76\u3002","og_url":"https:\/\/smallcapscn.x5view.co\/prescient-therapeutics-progress-innovative-pipeline-cancer-treatments-capital-raise\/","og_site_name":"smallcapsCN","article_published_time":"2022-08-25T04:30:32+00:00","article_modified_time":"2023-08-29T17:55:20+00:00","og_image":[{"width":640,"height":400,"url":"https:\/\/smallcapscn.x5view.co\/wp-content\/uploads\/2023\/08\/Prescient-Therapeutics-ASX-PTX-oncology-PTX-100-PTX-200-cancer-drugs.jpg","type":"image\/jpeg"}],"author":"Imelda Cotton","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Imelda Cotton"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/smallcapscn.x5view.co\/prescient-therapeutics-progress-innovative-pipeline-cancer-treatments-capital-raise\/","url":"https:\/\/smallcapscn.x5view.co\/prescient-therapeutics-progress-innovative-pipeline-cancer-treatments-capital-raise\/","name":"Prescient Therapeutics \u901a\u8fc7\u878d\u8d44\u63a8\u8fdb\u764c\u75c7\u6cbb\u7597\u7684\u521b\u65b0\u7ba1\u9053","isPartOf":{"@id":"https:\/\/smallcapscn.x5view.co\/#website"},"datePublished":"2022-08-25T04:30:32+00:00","dateModified":"2023-08-29T17:55:20+00:00","author":{"@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/cb7c1f9e2fb318e8ea5882e380e0d90e"},"description":"Prescient Therapeutics (ASX: PTX) \u542f\u52a8\u4e86\u4e00\u9879\u76ee\u6807\u4e3a 800 \u4e07\u6fb3\u5143\u7684\u878d\u8d44\uff0c\u4ee5\u4fdd\u6301\u5176\u5728\u5f00\u53d1\u521b\u65b0\u764c\u75c7\u548c\u7ec6\u80de\u7597\u6cd5\u7ba1\u9053\u65b9\u9762\u7684\u52bf\u5934\uff0c\u5e76\u8f6c\u5411\u9996\u6b21\u4eba\u4f53\u4e34\u5e8a\u7814\u7a76\u3002","breadcrumb":{"@id":"https:\/\/smallcapscn.x5view.co\/prescient-therapeutics-progress-innovative-pipeline-cancer-treatments-capital-raise\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/smallcapscn.x5view.co\/prescient-therapeutics-progress-innovative-pipeline-cancer-treatments-capital-raise\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/smallcapscn.x5view.co\/prescient-therapeutics-progress-innovative-pipeline-cancer-treatments-capital-raise\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/smallcapscn.x5view.co\/"},{"@type":"ListItem","position":2,"name":"Prescient Therapeutics \u901a\u8fc7\u878d\u8d44\u63a8\u8fdb\u764c\u75c7\u6cbb\u7597\u7684\u521b\u65b0\u7ba1\u9053"}]},{"@type":"WebSite","@id":"https:\/\/smallcapscn.x5view.co\/#website","url":"https:\/\/smallcapscn.x5view.co\/","name":"smallcapsCN","description":"Just another WordPress site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/smallcapscn.x5view.co\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/cb7c1f9e2fb318e8ea5882e380e0d90e","name":"Imelda Cotton","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/171e68cb4a3261dde883daa03441bfa3?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/171e68cb4a3261dde883daa03441bfa3?s=96&d=mm&r=g","caption":"Imelda Cotton"},"description":"Imelda Cotton has over 20 years experience as a journalist and communications professional. She has spent the bulk of her career in the resources sector, having also worked directly with oil and gas majors and as a journalist covering a vast array of ASX listed companies within the resources, energy, science and health sectors.","url":"https:\/\/smallcapscn.x5view.co\/?author=4"}]}},"_links":{"self":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/5697"}],"collection":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=5697"}],"version-history":[{"count":1,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/5697\/revisions"}],"predecessor-version":[{"id":15576,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/5697\/revisions\/15576"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/media\/19343"}],"wp:attachment":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=5697"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=5697"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=5697"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}